Imvotamab (IGM-2323) is an IgM-based CD20 x CD3 bispecific antibody T cell engager for the treatment of B cell non-Hodgkin’s lymphoma (NHL.) We believe that imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing cancer cells with more power (avidity) compared to an IgG bispecific antibody with only one binding unit for CD20.

Imvotamab

Harnessing T cells to address non-Hodgkin’s lymphoma

Further, the extra binding units of imvotamab may prove to be particularly advantageous for those cancer cells that express relatively lower amounts of CD20 on the cell surface, such as when CD20 expression has been reduced due to prior treatment with anti-CD20 antibodies.

Imvotamab has also been shown to have good target cell killing efficacy combined with a lower cytokine release profile associated with the T cell directed cellular cytotoxicity (TDCC) mechanism of action compared to an IgG based CD20 x CD3 antibody with the same CD20 and CD3 binding units, when tested in vitro with human T cells and human B cells.

 

We are currently evaluating the safety and efficacy of imvotamab in clinical trials for patients who have failed previous treatments for NHL.

< SEE OUR PIPELINE
< MORE INFORMATION ON OUR CLINICAL TRIAL